Aim: The objective of this study was to develop and validate a brief tool, the Dual Diagnosis Screening Instrument (DDSI), to screen psychiatric disorders in substance users in treatment and nontreatment-seeking samples. Methods: A total of 827 substance users (66.5% male, mean age 28.6 ± 9.9 years) recruited in treatment (in- and outpatient) and nontreatment (substance user volunteers in university research studies) settings were assessed by trained interviewers using the DDSI and the Psychiatric Research Interview for Substance and Mental Disorders (PRISM) as the criterion standard. Both instruments were administered blind to the results of the other. Disorders obtained with the DDSI were compared to lifetime diagnoses obtained with the PRISM. Sensitivity, specificity, negative, and positive predictive values were estimated. Also test-retest reliability of the DDSI was assessed. Results: The DDSI showed a high sensitivity (=80%) for identifying lifetime depression, mania, psychosis, panic, social phobia, and specific phobia disorders. Specificity was =82% for those diagnoses. Test-retest κ showed excellent agreement (range 81-95%). The mean duration of the DDSI administration was 16.8 ± 2.5 min. Conclusion: The DDSI is a valid and easy-to-administer screening tool to detect possible psychiatric comorbidity among substance users.

Keywords:
Psychopathology, Dual diagnosis, Screening, Dual Diagnosis Screening Instrument
1.
Kranzler HR, Rounsaville BJ: Dual Diagnosis and Psychiatric Treatment: Substance Abuse and Comorbid Disorders, ed 2. New York, Dekker, 2004.
2.
Brady KT, Verduin ML, Tolliver BK: Treatment of patients comorbid for addiction and other psychiatric disorders. Curr Psychiatry Rep 2007;9:374-380.
3.
Pierucci-Lagha A, Gelernter J, Feinn R, Cubells JF, Pearson D, Pollastri A, Farrer L, Kranzler HR: Diagnostic reliability of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). Drug Alcohol Depend 2005;80:303-312.
4.
Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R: Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 2004;161:1231-1237.
5.
Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R: Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 2006;163:689-696.
6.
Morgello S, Holzer CE III, Ryan E, Young C, Naseer M, Castellon SA, Frol AB, Atkinson JH, Gelman BB, Grant I, Singer EJ: Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium. Int J Methods Psychiatr Res 2006;15:131-138.
7.
Torrens M, Rossi PC, Martinez-Riera R, Martinez-Sanvisens D, Bulbena A: Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system? Subst Use Misuse 2012;47:1005-1014.
8.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33.
9.
Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV III, Hahn SR, Brody D, Johnson JG: Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 Study. JAMA 1994;272:1749-1756.
10.
Broadhead WE, Leon AC, Weissman MM, Barrett JE, Blacklow RS, Gilbert TT, Keller MB, Olfson M, Higgins ES: Development and validation of the SDDS-PC screen for multiple mental disorders in primary care. Arch Fam Med 1995;4:211-219.
11.
Zimmerman M, Sheeran T, Chelminski I, Young D: Screening for psychiatric disorders in outpatients with DSM-IV substance use disorders. J Subst Abuse Treat 2004;26:181-188.
12.
Perez GB, Garcia FL, de Vicente Manzanaro MP, Oliveras Valenzuela MA: Validation of the Psychiatric Diagnostic Screening Questionnaire (PDSQ) in a Spanish sample of alcoholic patients (in Spanish). Adicciones 2010;22:199-205.
13.
Castel S, Rush B, Kennedy S, Fulton K, Toneatto T: Screening for mental health problems among patients with substance use disorders: preliminary findings on the validation of a self-assessment instrument. Can J Psychiatry 2007;52:22-27.
14.
Magruder KM, Sonne SC, Brady KT, Quello S, Martin RH: Screening for co-occurring mental disorders in drug treatment populations. J Drug Issues 2005;35:593-605.
15.
Lincoln AK, Liebschutz JM, Chernoff M, Nguyen D, Amaro H: Brief screening for co-occurring disorders among women entering substance abuse treatment. Subst Abuse Treat Prev Policy 2006;1:26.
16.
Spitzer RL, Kroenke K, Williams JB: Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999;282:1737-1744.
17.
Delgadillo J, Payne S, Gilbody S, Godfrey C, Gore S, Jessop D, Dale V: How reliable is depression screening in alcohol and drug users? A validation of brief and ultra-brief questionnaires. J Affect Disord 2011;134:266-271.
18.
Carroll JFX, McGinley JJ: A screening form for identifying mental health problems in alcohol/other drug-dependent persons. Alcohol Treat Quart 2001;19:33-47.
19.
Sacks S, Melnick G, Coen C, Banks S, Friedmann PD, Grella C, Knight K, Zlotnick C: CJDATS Co-Occurring Disorders Screening Instrument (CODSI) for Mental Disorders (MD): a validation study. Crim Justice Behav 2007;34:1198-1216.
20.
Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lepine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martinez-Alonso M, Matschinger H, Mazzi F, Morgan Z, Morosini P, Palacin C, Romera B, Taub N, Vollebergh WA: Sampling and methods of the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;420:8-20.
21.
Torrens M, Martin-Santos R, Samet S: Importance of clinical diagnoses for comorbidity studies in substance use disorders. Neurotox Res 2006;10:253-261.
22.
Cuenca-Royo AM, Sanchez-Niubo A, Forero CG, Torrens M, Suelves JM, Domingo-Salvany A: Psychometric properties of the CAST and SDS scales in young adult cannabis users. Addict Behav 2012;37:709-715.
23.
Gilchrist G, Blazquez A, Torrens M: Psychiatric, behavioural and social risk factors for HIV infection among female drug users. AIDS Behav 2011;15:1834-1843.
24.
Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT: Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction 2008;103:284-293.
25.
Martin-Santos R, Torrens M, Poudevida S, Langohr K, Cuyas E, Pacifici R, Farre M, Pichini S, de la Torre R: 5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study. Addict Biol 2010;15:15-22.
26.
Yubero-Lahoz S, Pardo R, Farre M, O'Mahony B, Torrens M, Mustata C, Perez-Mana C, Carbo ML, de la Torre R: Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet 2011;50:319-329.
27.
Torrens M, Gilchrist G, Domingo-Salvany A: Psychiatric comorbidity in illicit drug users: substance-induced versus independent disorders. Drug Alcohol Depend 2011;113:147-156.
28.
Ramos-Quiroga JA, Diaz-Digon L, Comin M, Bosch R, Palomar G, Chalita JP, Roncero C, Nogueira M, Torrens M, Casas M: Criteria and Concurrent Validity of Adult ADHD Section of the Psychiatry Research Interview for Substance and Mental Disorders. J Atten Disord 2013 (E-pub ahead of print).
29.
Fleiss JL, Levin BA, Paik MC: Statistical Methods for Rates and Proportions, ed 3. New York, Wiley, 2003.
30.
Fein G, Di Sclafani V, Finn P, Scheiner DL: Sub-diagnostic psychiatric comorbidity in alcoholics. Drug Alcohol Depend 2007;87:139-145.
31.
Pani PP, Maremmani I, Trogu E, Gessa GL, Ruiz P, Akiskal HS: Delineating the psychic structure of substance abuse and addictions: should anxiety, mood and impulse-control dysregulation be included? J Affect Disord 2010;122:185-197.
32.
Van den Bosch LM, Verheul R: Patients with addiction and personality disorder: Treatment outcomes and clinical implications. Curr Opin Psychiatry 2007;20:67-71.
33.
Fenton MC, Keyes K, Geier T, Greenstein E, Skodol A, Krueger B, Grant BF, Hasin DS: Psychiatric comorbidity and the persistence of drug use disorders in the United States. Addiction 2012;107:599-609.
34.
Dakwar E, Nunes EV, Bisaga A, Carpenter KC, Mariani JP, Sullivan MA, Raby WN, Levin FR: A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers. Am J Addict 2011;20:441-446.
35.
Samet S, Fenton MC, Nunes E, Greenstein E, Aharonovich E, Hasin D: Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. Addiction 2013;108:115-123.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.